Epistem Receives a Prestigious FP7 Grant Award
News Aug 12, 2013
Epistem plc has announced that it has been awarded funding of EUR1.5 million over a three year period by the European Commission's 7th Framework Programme as part of a EUR6.0 million consortium project (Grant no. 601851) for the development of Point of Care Hepatitis C assays.
The PoC-HCV consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Qlucore (Sweden) and Biosurfit (Portugal).
The primary objective of the PoC-HCV consortium is to provide PoC diagnostic and predictive tests that enable tangible improvements in the health and quality of life of chronic Hepatitis C patients, while simultaneously helping to manage the rising cost of medical treatment.
It is an approach that capitalizes on the consortiums combined expertise spanning leading edge miniaturized molecular testing, lab-on-a-disk systems and treatment algorithm design.
These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.
Epistem will develop a number of tests on Genedrive® our hand-held CE-IVD marked PCR platform that provides rapid genotype tests results.
The assays which Epistem will develop include tests to detect and genotype the HCV virus, ascertain the IL-28b genotype of HepC infected patients to aid in the selection of patients who will respond to treatment with pegylated-interferon / ribavirin therapy and develop HepC viral load tests to monitor patient treatments.
Commenting on the successful Grant Application, Matthew Walls, CEO said "This support from the European Union will enable us to accelerate the development of a new range of affordable diagnostic and predictive tests that that will assist in the rapid and appropriate treatment of patients suffering with Hepatitis C in developed and under-developed countries. It also enables us to work together with internationally recognized leaders in HepC research and other leading SME's to develop tests that are highly sensitive and can be used in Point of Care settings."
New Approach Identifies Important Undiscovered Functions of ProteinsNews
Scientists have developed a new method to discover which surface contacts on proteins are critical for these cellular interactions. The novel approach shows that essential new functions can be uncovered even for well-studied proteins, and has significant implications for therapeutic drug development, which depends heavily on how drugs physically interact with their cellular targets.READ MORE
New Rapid Test for Valley Fever Should Help Reduce Diagnosis DelaysNews
November saw a spike if cases of Valley fever. Fortunately, the recent—and timely—approval of a new rapid assay test for Valley fever should reduce delays in diagnosing the respiratory fungal infections—a frequent problem in treating the disease, which is caused by spores endemic to soils in the U.S. Southwest.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE